Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk
- 2.9k Downloads
Gut microbiota has been recently established to have a contributory role in the development of cardiometabolic disorders, such as atherosclerosis, obesity, and type 2 diabetes. Growing interest has focused on the modulation of gut microbiota as a therapeutic strategy in cardiovascular diseases and metabolic disorders. In this paper, we have reviewed the impact of gut microbiota on metabolic disorders and cardiovascular disease risk, focusing on the newest findings in this field.
KeywordsCardiovascular disease Gut microbiota Obesity Type 2 diabetes Platelets
Compliance with Ethics Guidelines
Conflict of Interest
Luca Miele, Valentina Giorgio, Maria Adele Alberelli, Erica De Candia, Antonio Gasbarrini, and Antonio Grieco declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•Go AS, Mozaffarian D, Roger VL, et al. American heart association statistics committee and stroke statistics subcommittee. Executive summary: heart disease and stroke statistics—2014 update: a report from the American heart association. Circulation. 2014;129(3):399–410. This study provides the most recent updates on the cardiovascular diseases prevalence all over the world. CrossRefPubMedGoogle Scholar
- 5.••Palm NW, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. Clin Immunol. 2015;159(2):122–7. doi: 10.1016/j.clim.2015.05.014. This review explains on the importance of individual gut microbes and on their link with individual disease susceptibility.
- 11.•Pacheco AR, Sperandio V. Enteric pathogens exploit the microbiota-generated nutritional environment of the gut. Microbiol Spectr. 2015;3(3). This paper gives an interesting overview of microbiota and nutrient generation in the gut.Google Scholar
- 16.•Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 2014;41(2):296–310. This study provides a description of how a chemical communication between the intestinal symbionts and PXR regulates mucosal integrity through a pathway that involves signaling by TLR4. PubMedCentralCrossRefPubMedGoogle Scholar
- 21.•Kim MH, Kang SG, Park JH, et al. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013;145(2):396–406.e1-10. This paper describes the regulation of the immune response by SCFAs and their receptors in the intestines of mice. The pathways described mediate protective immunity and tissue inflammation and may have applications in the clinical practice. CrossRefPubMedGoogle Scholar
- 25.••De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1–2):84–96. Underlying mechanisms by which soluble dietary fibers promote benefits on body weight and glucose control are poorly understood. This papers describes the most recent evidence in the field. CrossRefPubMedGoogle Scholar
- 30.••Balmer ML, Slack E, de Gottardi A, et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014;6(237), 237ra66. This paper interestingly describes how the liver may act as a functional vascular firewall clearing commensals that have penetrated intestinal circuits. Describes mechanisms may have new therapeutic applications. CrossRefPubMedGoogle Scholar
- 39.••Moya-Pérez A, Neef A, Sanz Y. Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by restoring the lymphocyte-macrophage balance and gut microbiota structure in high-fat diet-fed mice. PLoS ONE. 2015;10(7), e0126976. This paper shows mechanisms through which Bifidobacterium pseudocatenulatum reduces systemic inflammation and improves metabolic dysfunction in obese mice. This finding may have a clinical application in the treatment of obesity. PubMedCentralCrossRefPubMedGoogle Scholar
- 50.•Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–35. This paper support the hypothesis that the modulation of gut microbiota may increase the antidiabetic effects of metformin.Google Scholar
- 51.•Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–71. This Authors explore the mechanisms of bacterial regulation of the cross-talk between the host and gut microbiota and provide data on metabolic function of gut bacteria (i.e., A. muciniphila).Google Scholar
- 58.Cappuccio FP, Oakeshott P, Strazzullo P, et al. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross-sectional population based study. BMJ. 2002;325:1271.PubMedCentralCrossRefPubMedGoogle Scholar
- 69.••Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84. Evidence of link between production of TMAO and intestinal microbiota. The TMAO levels are associated with increased risk of major cardiovascular events. Google Scholar